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Upper tract urothelial carcinoma has a luminal-
papillary T-cell depleted contexture and activated
FGFR3 signaling
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Mark A. Rubin 1,2,3,8,11, Seth P. Lerner12, Surena F. Matin13, Olivier Elemento3,5,6,8,16 &
Bishoy M. Faltas 3,4,8,14,16
Upper tract urothelial carcinoma (UTUC) is characterized by a distinctly aggressive clinical
phenotype. To deﬁne the biological features driving this phenotype, we performed an inte-
grated analysis of whole-exome and RNA sequencing of UTUC. Here we report several key
insights from our molecular dissection of this disease: 1) Most UTUCs are luminal-papillary;
2) UTUC has a T-cell depleted immune contexture; 3) High FGFR3 expression is enriched in
UTUC and correlates with its T-cell depleted immune microenvironment; 4) Sporadic UTUC
is characterized by a lower total mutational burden than urothelial carcinoma of the bladder.
Our ﬁndings lay the foundation for a deeper understanding of UTUC biology and provide a
rationale for the development of UTUC-speciﬁc treatment strategies.
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Upper tract urothelial carcinoma (UTUC) accounts for5–10% of all urothelial carcinomas (UCs)1. UTUC is adistinct clinical entity with an aggressive clinical behavior
and a more advanced presentation compared to urothelial
carcinoma of the bladder (UCB)1. Recently, the Cancer Genome
Atlas (TCGA) study classiﬁed UCB into ﬁve molecular subtypes
(luminal-papillary, luminal-inﬁltrated, luminal, basal/squamous,
neuronal). Since TCGA did not include UTUC2, it is currently
unknown whether UTUC recapitulates the same molecular sub-
types2–6. Furthermore, our understanding of the immune milieu
of UTUC is incomplete.
These knowledge gaps have hindered the development of
effective UTUC-speciﬁc therapeutic strategies. To dissect the
central biological features of UTUC’s tumor and immune cell
compartments, we analyzed whole-exome sequencing (WES) and
RNA sequencing (RNAseq) data from high-grade UTUC tumors
from patients at three different institutions [Weill Cornell Med-
icine (WCM), Baylor College of Medicine and MD Anderson
Cancer Center (BCM–MDACC)]. We used whole-exome and
RNAseq data from UCB tumors from the TCGA cohort as a
comparison cohort5. This enabled us to deﬁne the biological
differences between UC arising from the upper and lower urinary
tracts and to gain insights into the unique mechanisms that drive
UTUC biology. We show that UTUC is predominantly luminal-
papillary and T-cell depleted. We identify FGFR3 as a putative
regulator of UTUC’s immune contexture through attenuation of
interferon gamma (IFNG) signaling. Finally, we report that the
tumor mutational burden in sporadic UTUC is lower than UCB,
despite reduced expression of DNA mismatch repair (MMR)
transcripts and proteins.
Results
UTUC and UCB mutational proﬁles. We performed whole
exome sequencing (WES) of 37 UTUC primary tumor–normal
pairs. We only included patients with high-grade UTUC tumors.
Most patients were former or current smokers (64.8%) (Supple-
mentary Table 1). We identiﬁed FGFR3 mutations in 11/37
(29.7%) (Fig. 1a), a signiﬁcantly higher frequency compared to
the 17/124 (13.7%) mutations detected in TCGA UCB (Wilcoxon
test P= 0.04) (Fig. 1b). In contrast, we found no signiﬁcant dif-
ference in the prevalence of mutations in chromatin modifying
(KMT2D, ARID1A, KDM6A), receptor tyrosine kinase path-
way (PIK3CA, HRAS), transcription factor (RXRA, KLF5, ELF3),
and cell cycle regulation (TP53, RB1, CDKN1A, CDKN2A) genes
between our UTUC and TCGA UCB cohorts (Fig. 1a, b).
To deﬁne the mutagenic mechanisms that shape the genomic
landscape of UTUC, we performed a mutational signature
analysis to identify the prevalent Catalog of Somatic Mutations
in Cancer (COSMIC) signatures in the WCM UTUC, BCM-
MDA UTUC, and TCGA UCB cohorts7. We identiﬁed the
COSMIC APOBEC-associated signatures 2 and 13 as the
dominant mutational signatures in UTUC (Fig. 1c). We also
identiﬁed C>T transitions at CpG dinucleotides. This signature is
characterized by high numbers of small indels at mono/
polynucleotide repeats and is associated with defective MMR
(Fig. 1d). Another mutational signature in UTUC was found to be
related to defective nucleotide excision repair (NER)8 (Fig. 1d).
Collectively, these data suggest that these three mutational
processes (APOBEC, MMR, NER) (Fig. 1d) are responsible for
the majority of mutations in UTUC.
Somatic downregulation of DNA damage repair (DDR) genes
in UTUC. The association between germline mutations in MMR
genes that cause microsatellite instability (MSI) and Lynch
syndrome and increased susceptibility to the development of
UTUC is well established9–11. However, it is unclear whether
non-Lynch (sporadic) UTUC patients have defective DDR and an
increased mutational burden. To deﬁne whether somatic dysre-
gulation of DDR genes could play a similar role in inducing a
hypermutated phenotype in non-Lynch UTUC patients, we
assessed the mRNA expression level of DDR pathway genes in
UTUC (WCM, BCM-MDA) and UCB (TCGA). We focused our
analysis on identifying differentially expressed genes in the
canonical DDR pathways [MMR, base-excision repair (BER),
NER, homologous recombination (HR), non-homologous end
joining (NHEJ), Fanconi anemia (FA), translesion synthesis
(TLS)] comparing UTUC with UCB (Fig. 2a). We identiﬁed a
signiﬁcant somatic dysregulation of 35 canonical DDR genes in
UTUC (Fig. 2a). We analyzed germline WES data from patients
in our UTUC cohorts (WCM, BCA-MDA) and identiﬁed no
germline mutations in the canonical MMR genes (MLH1, PMS2,
MSH2, MSH6). Interestingly, we observed signiﬁcantly lower
somatic mRNA expression of three canonical MMR genes:
MLH1, MSH2, and MSH6 in UTUC tumors compared to TCGA
UCB tumors (Fig. 2a). To determine whether this decreased
mRNA levels further translated into a low expression of MMR
proteins, we used immunohistochemistry (IHC) to quantify their
expression in WCM UTUC tumors (n= 16) compared to stage-
matched WCM UCB tumors (n= 14). We found that the levels of
MLH1, PMS2, MSH2, and MSH6 proteins were signiﬁcantly
lower in UTUC tumors (Fig. 2b, c). This conﬁrmed that lower
expression of these proteins is a characteristic feature of UTUC
even in the absence of germline or somatic mutations in the
respective genes in the WCM UTUC cohort.
To determine whether downregulation of these proteins
impaired DNA MMR, we examined WES data for short tandem
repeats (MSI) using the MSI sensor program12 that calculates the
percentage of unstable microsatellites from UTUC and UCB
tumor–normal paired WES data. Surprisingly, the median MSI
sensor scores were similar in WCM UTUC and TCGA UCB.
Both were below the previously deﬁned threshold of 3.5, which
was shown to accurately classify microsatellite unstable tumors12
(Fig. 2d). Furthermore, WCM UTUC samples harbored a
signiﬁcantly lower mean total mutational burden (TMB)
compared to TCGA UCB tumors (2.91 versus 5.46 mutations
per MB) (Fig. 2e). This suggests that the somatic downregulation
of MMR proteins is insufﬁcient to produce MSI and is not a
major driver of mutagenesis in non-Lynch UTUC. Collectively,
these ﬁndings indicate that the decrease in the mRNA and
protein levels of MMR genes in sporadic UTUC does not
translate into MSI or a higher TMB.
UTUCs are predominantly luminal-papillary. To characterize
the gene expression proﬁles which deﬁne UTUC, we generated an
RNAseq meta-dataset from 32 UTUC tumors and the TCGA
UCB cohort. To ensure homogeneity, we performed sample
normalization of the data prior to standardization and ﬁtted the
quantiles of each sample’s raw data to be similar. We also com-
pared the z-scores of the mRNA expression of 40 housekeeping
genes among tumor samples from WCM UTUC, BCM-MDA
UTUC, and TCGA UCB and found no signiﬁcant differences for
the majority of these genes (Supplementary Fig. 1). Using the
University of North Carolina (UNC) 47-gene signature (BASE47)
classiﬁer3, we found that 27/32 (84.3%) of the UTUC tumors
clustered with the luminal subtype (Fig. 3a and Supplementary
Table 2) as opposed to only 59/128 (46.1%) in UCB2. To ensure
that this luminal expression pattern is a consistent biological
property of UTUC, we conﬁrmed this ﬁnding using several dif-
ferent methods. First, we interrogated the same meta-dataset
using two additional validated classiﬁers of urothelial carcinoma
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subtypes. When we applied the MDACC classiﬁer which divides
UC into luminal, basal, and p53-like subtypes4, we found that 22/
32 (68.7%) of UTUC tumors clustered with the luminal subtype
(Supplementary Fig. 2 and Supplementary Table 2) versus only
47/128 (36.7%) of UCB2. Using the recent TCGA classiﬁer which
segregates UC into luminal-papillary, luminal-inﬁltrated, luminal,
basal-squamous, and neuronal subtypes2, we conﬁrmed that
UTUC has a luminal-papillary phenotype (20/32, 62.5%), with
the majority of remaining UTUC tumors also exhibiting a
luminal expression proﬁle (8/12, 67%) (Supplementary Fig. 3 and
Supplementary Table 2). This is in contrast to 35/128 (27.3%) of
luminal-papillary UCB tumors in the TCGA UCB cohort, with
only a minority of the rest (35/93, 37.6%) also segregating with
luminal or luminal-inﬁltrated subtypes2. To conﬁrm these ﬁnd-
ings using a different approach, we used non-negative matrix
factorization (NMF)13, a sensitive unsupervised statistical method
to dissect and extract the key biological features of UTUC from
our high dimensional RNAseq dataset13. The NMF analysis
revealed three principal components characterized by luminal/
carcinoma in situ (CIS)-low, basal/squamous-like, and extra-
cellular matrix (ECM)/epithelial–mesenchymal transition (EMT)-
related gene sets2. Principal component analysis (PCA) was then
performed on the coefﬁcients obtained from NMF to visualize the
separation of the three components (Fig. 3b). This demonstrated
that the luminal-papillary component is a deﬁning feature of
UTUC. Our results suggest that the majority of UTUCs represent
a distinct subset within the continuum of UC differentiation that
shares similar characteristics with the luminal-papillary subtype
of UCB.
UTUC has a T-cell depleted immune contexture. The immune
contexture of tumors is an essential determinant of the host’s
anti-cancerimmune response14 and clinical outcomes. To dissect
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Fig. 1 Genomic differences between upper tract urothelial carcinoma (UTUC) and urothelial bladder carcinoma (UCB). a Prevalence of frequent somatic
genomic alterations in 37 patients with UTUC from the Weill Cornell Medicine (WCM UTUC) and Baylor College of Medicine–MD Anderson Cancer
Center (BCM–MDACC UTUC) cohorts. The somatic mutational rate for each tumor is represented by vertical barplots (total number of non-silent
mutations per megabase (MB)). Patient and tumor characteristics are represented on the top right. b Horizontal barplot showing differences in mutational
frequencies between WCM UTUC (orange bars), BCM-MDA UTUC (blue bars), and TCGA UCB (green bars) cohorts for frequently mutated genes.
Asterisk indicates statistically signiﬁcant changes in paired comparison between BCM-MDA UTUC and TCGA UCB (*Fisher’s Exact test P= 0.001).
c Heatmap of a cosine similarity matrix of COSMIC mutational signatures and observed mutational signatures in UTUC (WCM, BCM-MDA) and TCGA
UCB cohorts. UTUC signature clusters with COSMIC signatures 2, 13 (APOBEC-associated). d Dominant mutational signatures in UTUC (top panel)
include the C>T CpG signature, attributable to mutagenesis via defective mismatch repair (MMR) (COSMIC signature 6), the ERCC2 signature, consistent
with COSMIC signature 5, and the APOBEC signatures (COSMIC signatures 2 and 13) resulting from the endogenous cytidine deamination induced by the
APOBEC3 enzyme family. TCGA UCB mutational signatures are shown for comparison (bottom panel)
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the gene expression proﬁle of UTUC that characterizes its
immune contexture, we developed a 170-gene classiﬁer com-
prising key immune genes (Supplementary Table 3). This classi-
ﬁer separated tumors independent of their anatomical origin into
T-cell inﬂamed, and T-cell-depleted clusters. Interestingly, the
majority of UTUC (WCM, BCM-MDA) tumors (28/32, 87.5%)
were T-cell depleted (Fig. 4a) with consistent downregulation of
T-cell related (CD8A, CCL2, CCL3, CCL4, CXCL9, CXCL10)15
and IFNG signaling genes16 (Fig. 4a). In contrast, TCGA UCB
tumors were almost evenly distributed between T-cell inﬂamed
(57/128, 44.5%) and T-cell depleted (71/128, 55.5%) immune
subtypes (UTUC vs. UCB (Fisher’s exact test P= 0.0009)
(Fig. 4a).
FGFR3 is a putative driver of UTUC’s immune-depleted con-
texture. To identify the signaling pathways that characterize
UTUC’s immune contexture, we performed gene expression
analysis to detect outliers. We detected outlier FGFR3 mRNA
expression in 14/32 (43.7%) of the tumors in our UTUC (WCM,
BCM-MDA) cohorts (Fig. 4b). We identiﬁed nine activating
missense mutations in these tumors. These ﬁndings suggest that
activated FGFR3 signaling potentially plays a prominent role in
the distinct gene expression proﬁle of UTUC.
We then went on to assess whether FGFR3 is differentially
expressed between T-cell inﬂamed and T-cell-depleted tumors.
Indeed, we identiﬁed signiﬁcantly higher FGFR3 expression in the
T-cell-depleted cluster which harbored the majority of the UTUC
tumors (Fig. 4c). We interrogated the functional link between
FGFR3 signaling and the T-cell-depleted phenotype observed in
UTUC. We reanalyzed a previously published dataset of mRNA
expression from the RT-112 UC cell line following doxycycline
(dox)-inducible short hairpin RNA (shRNA) knockdown of
FGFR317,18. We found that several IFNG response genes
including BST2, MX2, IRF9, GBP2 were upregulated after
FGFR3 knockdown (Fig. 4d). Conﬁrming these results, we
found that BST2 and IRF9 were signiﬁcantly downregulated in
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Fig. 3 UTUC is predominantly luminal. a Supervised consensus clustering and heatmap of mRNA expression data from WCM UTUC, BCM-MDA UTUC,
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the T-cell-depleted cluster which harbored the majority of
UTUCs in our patient cohort (Supplementary Fig. 4). We also
found a statistically signiﬁcant upregulation of other IFNG
response genes in the FGFR3 shRNA+ dox dataset when
compared to the control (ctl)+ dox dataset (Fig. 4e). To conﬁrm
this observation and deﬁne whether pharmacologic inhibition of
FGFR3 will have a similar effect on IFNG response genes
(Supplementary Table 4), we tested the effects of erdaﬁtinib, a
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small molecule FGFR3 inhibitor, in three different UC cell lines
(RT-112, RT-4, and SW780). These cell lines harbor FGFR3 fusions
(RT-112, RT-4: FGFR3-TACC3; SW780: FGFR3-BAIAP2L1)
resulting in constitutively activated FGFR3 signaling19. We found
that treatment with erdaﬁtinib led to a signiﬁcant upregulation of
BST2, a hallmark of activated interferon signaling (Fig. 4f).
Collectively, these ﬁndings show that FGFR3 plays an important
role in shaping the T-cell-depleted phenotype in UTUC in a cancer-
cell autonomous manner.
Discussion
We performed a comprehensive genomic and transcriptomic
analysis of UTUC to identify the key biological features that
differentiate UTUC from UCB. We found that the majority of
UTUC tumors are luminal-papillary and T-cell depleted.
Previous studies identiﬁed a link between Lynch syn-
drome caused by germline mutations in MMR genes and
UTUC9–11. However, the vast majority of UTUCs arise spor-
adically (in non-Lynch syndrome patients). Our analysis aimed to
deﬁne whether sporadic UTUC patients had MSI or a higher
TMB, which are independent predictors of response to immune
checkpoint inhibition20,21. Our study revealed a lower TMB in
non-Lynch syndrome UTUC compared to UCB. We found that
the lower expression of canonical MMR mRNA and proteins in
non-Lynch UTUC was insufﬁcient to produce signiﬁcant MSI or
a higher TMB compared to UCB. Unlike the complete absence of
MSH2, MLH1, MSH6, or PMS2 or MLH1 protein expression
observed in Lynch syndrome patients caused by loss-of-function
germline mutations, the incomplete loss of these proteins
observed in sporadic UTUC is not sufﬁcient to cause MSI22. Even
low MMR protein expression is adequate for maintaining func-
tional MMR and preserving microsatellite stability23. These
results are also consistent with a recent study showing MSI sensor
scores < 3.5 in the majority of non-Lynch syndrome UTUC
patients24. Taken together, our ﬁndings suggest that, contrary to
the prevalent notion, sporadic UTUC is not hypermutated. This
is especially important when considered in conjunction with our
data showing that the majority of sporadic UTUCs are also
consistently luminal-papillary and T-cell depleted. This new
understanding of the mutational landscape and immune con-
texture in non-Lynch syndrome UTUCs (which constitute the
majority of cases) further explains the lack of higher response
rates of UTUC compared to UCB in clinical trials of immune
checkpoint inhibitors (ICIs)20,21. In a prospective phase 2 study
of advanced, post-platinum UC patients (including UTUC),
atezolizumab demonstrated the lowest response rates in the
luminal-papillary (cluster I) subtype compared to other sub-
types20. In a different trial, response to nivolumab was lower in
the luminal 1 (cluster I) UC tumors with low expression of IFNG
signature genes15.
We identiﬁed a putative role for upregulated FGFR3 in UTUC
in shaping the immune contexture of T-cell-depleted UTUC
tumors. This observation is consistent with the previously
described enrichment of the FGFR3 gene signature in luminal
UCB tumors2–6,25 and the association of FGFR upregulation with
T-cell depletion in tumors of pancreatic and breast origin14. We
observed a consistent increase in BST2 following pharmacologic
FGFR3 inhibition in three different UC cell lines that harbor
activating FGFR3 fusions. BST2 is a viral restriction factor which
is canonically induced by interferon26.This is also consistent with
the role of FGFR3 in blocking the Y701 tyrosine phosphorylation
required for STAT1 activation27. Taken together, these ﬁndings
provide putative mechanistic links between FGFR3 and IFNG
signaling and suggest that FGFR3 inhibition potentially remodels
the immune contexture of UTUC by upregulating interferon
response genes to reverse its T-cell-depleted phenotype.
Our observations also provide a rationale for combining
FGFR3 inhibitors with PD-1/PD-L1 inhibitors as a targeted
therapeutic strategy to modulate the T-cell-depleted phenotype of
UTUC. Preliminary clinical trial results using two pan-FGFR
inhibitors, erdaﬁtinib, and BGJ398 in several cancers enriched for
FGFR genomic alterations including urothelial carcinoma, are
encouraging28,29. Erdaﬁtinib was granted accelerated approval by
the FDA in relapsed/refractory metastatic bladder cancer on
the basis of phase 2 trial results showing a response rate of 32.2%
in 87 patients with tumors that harbored actionable FGFR
alterations30. Our ﬁndings suggest that clinical trials of FGFR3
inhibitors as single agents or in combination with immune
checkpoint blockade as a UTUC-targeted therapeutic strategy is
warranted. This strategy is also potentially applicable to other
tumor types harboring FGFR3-activating molecular alterations.
Our study has multiple strengths. We used different approa-
ches to conﬁrm that the predominantly luminal-papillary phe-
notype of UTUC is a consistent biological feature. In a previous
study, unsupervised clustering of RNAseq data from both high-
grade and low-grade UTUC was used to divide UTUC into four
molecular subtypes31. Here, we used an alternative approach to
position high-grade UTUC within the continuum of UC biology.
Fig. 4 FGFR3 plays an important role in the T-cell-depleted immune contexture of UTUC. a UTUC is T-cell depleted. Supervised consensus clustering of
WCM UTUC, BCM-MDA UTUC, and TCGA UCB tumors according to a 170-immune gene signature classiﬁes tumors into T-cell depleted (with lower
expression of classiﬁer genes), and T-cell inﬂamed (with higher expression of classiﬁer genes) clusters (Fisher’s exact test P= 9 × 10-5). b FGFR3 is an
expression outlier in UTUC tumors. WCM UTUC and BCM-MDA UTUC tumors are represented on the x-axis, and normalized z-scores of gene’s expression
represented on the y-axis. c Boxplots of mean expression of FGFR3 and PPARG genes [in Fragments Per Kilobase of transcript per Million mapped
reads (FPKM)] within the T-cell-depleted versus T-cell inﬂamed clusters (FGFR3: Wilcoxon test P= 1.3 × 10−6; PPARG: Wilcoxon test P= 1.1 × 10−5). The
horizontal lines within the boxplots indicate the mean, boundaries of the boxes indicate the 25th-percentile and 75th-percentile, and the whiskers indicate
the highest and lowest values of the results. d Interferon gamma (IFNG)-response genes are upregulated in response to FGFR3 knockdown. Volcano plot of
differential fold expression of genes (logFC < 0 vs. logFC > 0; t-test adjusted P < 0.05) in FGFR3 shRNA+Doxycycline compared to control+Doxycycline
UCB RT-112 cells (BST2: P < 0.001; GBP2: P= 0.038; IRF9: P= 0.005; MX2: P= 0.003). e Enrichment map of cancer-related pathways with signiﬁcant
positive and negative enrichment in FGFR3 shRNA UCB RT-112 cells. Node size corresponds to the number of genes within each gene set. The up-regulated
nodes were represented in red while the down-regulated clusters were represented in blue. Overall, 476/3534 gene sets were upregulated, and 651/3534
gene sets were downregulated (t-test P < 0.05; false discovery rate (FDR) < 0.25). Several IFNG response gene sets were enriched after FGFR3 blockade
(t-test P < 0.001; FDR= 0.062). f Pharmacologic inhibition of FGFR3 upregulates IFNG-response gene BST2 using two different primer pairs (BST2 #1, BST2
#2). Barplots showing relative fold increase (mean ± SD) of mRNA levels of BST2 (BST2 #1 and BST2 #2) after treatment with erdaﬁtinib at 1 and 5 nM
compared to DMSO vehicle in RT-112, RT-4, and SW780 cells. No statistically signiﬁcant differences were observed in the expression of BST2 between the 1
and 5 nM erdaﬁtinib conditions in any of the tested cell lines (statistical signiﬁcance level is denoted by asterisks *t-test P < 0.05, **P < 0.01, ***P < 0.001, n.s:
non-signiﬁcant). Error bars show standard deviation (S.D.) for each condition
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Our study also has several limitations. Even though we included
patients from three major academic institutions, our cohort is still
limited by sample size due to the relative rarity of this tumor type.
Further conﬁrmation of our ﬁndings in larger UTUC cohorts is
warranted. Future studies also need to examine the stability of the
molecular proﬁles we identiﬁed across matched primary and
metastatic UTUC tumors.
In summary, our ﬁndings lay the foundation for a deeper
understanding of the key features of the biology of UTUC. Based
on this knowledge, we provide a roadmap for the rational clinical
development of targeted and immunotherapeutic strategies that
are speciﬁc to UTUC but also potentially applicable to other
tumor types harboring FGFR3-activating molecular alterations.
Methods
Patient enrollment and tissue acquisition. The study was approved by our
Institutional Review Boards (Weill Cornell Medicine (WCM)/New York-
Presbyterian (NYP) IRB protocols for Tumor Biobanking—0201005295, GU tumor
Biobanking—1008011210, Urothelial Cancer Sequencing—1011011386, Compre-
hensive Cancer Characterization by Genomic and Transcriptomic Proﬁling—
1007011157 and Precision Medicine—1305013903). Banked excess tissue was
collected from nephroureterectomy specimens of patients with a diagnosis of high-
grade UTUC. UTUC high-grade samples were obtained from patients under
protocols approved by institutional review boards using endoscopic biopsy or
surgical resection at BCM and MDACC31. All tumor samples consisted of con-
ventional UC. Samples were selected based on pathologic diagnosis according to
standard guidelines for UTUC1,32. All pathology specimens were reviewed and
reported by board-certiﬁed genitourinary pathologists in the Department of
Pathology at WCM/NYP, BCM and MDA. Clinical charts were reviewed by the
authors (P.J.V., T.J.M., S.F.M., S.P.L., B.M.F.) to record patient demographics,
tobacco use, treatment history, anatomic site, the presence of concurrent bladder
cancer, pathologic grade and stage using tumor, node, metastasis (TNM) system.
DNA for WES was extracted from tumors and matched normal tissues and RNA
was puriﬁed from tumors for RNAseq.
DNA extraction and WES. For WCM UTUC samples, we used our established
WES protocol33,34. After macrodissection of target lesions, tumor DNA was
extracted from formalin-ﬁxed, parafﬁn-embedded (FFPE) or cored OCT-
cryopreserved tumors using the Promega Maxwell 16 MDx (Promega, Madison,
WI, USA). Germline DNA was extracted from normal kidney tissue adjacent to the
tumor, using the same method. Pathological review by one of the study pathologists
(B.D.R., J.M.M., M.A.R.) conﬁrmed the diagnosis and determined tumor content.
A minimum of 200 ng of DNA was used for WES. DNA quality was determined by
TapeStation Instrument (Agilent Technologies, Santa Clara, CA) and was con-
ﬁrmed by real-time PCR before sequencing. Sequencing was performed using
Illumina HiSeq 2500 (2 × 100 bp). A total of 21,522 genes were analyzed with an
average coverage of 85× using Agilent HaloPlex Exome (Agilent Technologies,
Santa Clara, CA). For BCM-MDA samples, DNA was puriﬁed from tumor and
matched normal tissues and used for WES31.
WES data processing pipeline. All the WCM samples data were processed
through the computational analysis pipeline of the Institute for Precision Medicine
at Weill Cornell, New York Presbyterian Hospital (IPM-Exome-pipeline)32. Raw
reads quality was assessed with FASTQC33. Pipeline output includes segment DNA
copy number data, somatic copy-number aberrations (CNAs) and putative somatic
single-nucleotide variants (SNVs). Bioinformatic analysis of BCM-MDA samples
data was performed31.
Single nucleotide variants. We developed a consensus somatic SNVs calling
pipeline to enhance the accuracy of these calls for WCM samples. SNVs were
identiﬁed in the paired tumor–normal samples using MuTect2, Strelka, VarScan,
and SomaticSniper, and only the SNVs identiﬁed by at least two mutation callers
were retained. Indels (insertions or deletions) were identiﬁed using Strelka and
VarScan and only those identiﬁed by both tools were retained. The identiﬁed
somatic alterations were further ﬁltered using the following criteria: (a) read depth
for both tumor and matched normal samples was ≥ 10 reads, (b) the variant allele
frequency (VAF) in tumor samples was ≥ 5% and >3 reads harboring the mutated
allele, (c) the VAF of matched normal was ≤ 1% or there was just one read with
mutated allele. The variants were annotated using Oncotator (version 1.9); the
dbSNPs amongst the mutation calls, unless also found in the COSMIC database,
were ﬁltered out. For the IPMs samples, the promiscuous mutation calls, previously
identiﬁed internally as artifacts for Haloplex were also excluded from the ﬁnal list
of mutations. Tumor mutation burden (TMB) was calculated for each sample as
the number of mutations divided by the number of bases in the coverage space per
million. Somatic mutations were called via a standard cancer analysis pipeline at
the BCM Human Genome Sequencing Center and by using VARSCAN2 for BCM-
MDA samples31.
Mutational signature analysis. Somatic alterations identiﬁed from the WES
analysis pipeline were used to identify underlying patterns of mutational sig-
natures. The nonsynonymous SNVs were classiﬁed into the six base substitution
classes and the bases immediately to the 5′ and 3′ of the mutated base gave 16
different mutational contexts; hence there were 96 different base substitution
patterns in total. All base substitutions were reported in context of pyrimidines and
in 5′ to 3′ direction. The signatures were identiﬁed using the counts of 96 base
substitutions for each sample, based on the Bayesian NMF8. The signatures dis-
covered in the WCM UTUC, BCM-MDA UTUC and TCGA UCB cohorts were
compared to the 30 COSMIC signatures using hierarchal clustering of cosine
similarity amongst these signatures with ‘ward.D2’ linkage.
MMR histochemical expression and H-score calculation. Expression of MMR
proteins was assessed in 16 WCM UTUC tumors and 14 matched archival WCM
UCB. IHC was performed on 4-μm-thick formalin-ﬁxed parafﬁn-embedded tissue
sections using a Leica Bond III automated stainer. Mouse antibodies against MLH1
(G168-728, 1:25 dilution, BD Biosciences), PMS2 (A16-4, 1:100 dilution, BD Bios-
ciences), MSH2 (FE11, 1:200, EMD Millipore), and MSH6 (44/MSH6, 1:200, BD
Biosciences) were used. IHC slides were scanned at ×200 total magniﬁcation using a
single z-plane via an Aperio AT2 whole slide scanner (Leica Biosystems, San Diego,
CA, USA). The scanned images were loaded onto the HALOTM imaging analysis
platform (Indica Labs, Corrales, New Mexico, USA). Study pathologists manually
selected tumor areas for automated image scoring, and the HALOTM analysis
software determined the staining intensity of each tumor cell (0, 1+, 2+, 3+) and
percentage of tumor cells for each intensity level. H-scores were then calculated using
the formula [1×(% of cells with intensity of 1+)+2×(% cells 2+)+3×(% cells 3+)]
with possible scores thus ranging from 0 to 300.
Computational detection of MSI. MSI in WCM UTUC and TCGA UCB samples
was detected by MSI sensor. MSI sensor is a software tool that quantiﬁes MSI in
paired tumor–normal genome sequencing data and reports the somatic status of
corresponding microsatellite sites in the human genome12. MSIsensor score was
calculated by dividing the number of microsatellite unstable by the total number of
microsatellite stable (MS) sites detected. The cut-off for deﬁning MSI-high (MSI-
H) versus MS stable (MSS) samples was 3.5 (MSI-H > 3.5, MSS < 3.5)12.
Germline variant calling pipeline. Germline samples used in this study were
normal tissue from fresh frozen or formalin-ﬁxed parafﬁn-embedded tissue from
nephroureterectomy archival specimens of patients with a diagnosis of UTUC at
WCM35. We applied a germline variant calling pipeline based on the
Burrows–Wheeler Aligner (BWA), and the Genome Analysis Toolkit (GATK), for
base recalibration, realignment around indels and variant calling. We devised a
variant ﬁltering strategy to narrow down the most important and likely clinically
relevant variants. For each variant, we collected annotations from databases
including ClinVar and Exome Aggregation Consortium (ExAC, http://exac.
broadinstitute.org)36. Following the ACMG Standards and Guidelines regarding
classiﬁcation and interpretation of sequence variants37, the variants were classiﬁed
into ﬁve categories: Pathogenic Likely Pathogenic, Likely Benign, Benign and
variants of unknown signiﬁcance. Germline samples from the BCM-MDA cohort
were previously analyzed31. None of the included BCM-MDA UTUC patients had
a diagnosis of Lynch syndrome31.
RNA extraction, RNAseq, and data analysis. RNA was extracted from frozen
material for RNA-sequencing (RNA-seq) using Promega Maxwell 16 MDx
instrument, (Maxwell 16 LEV simplyRNA Tissue Kit (cat. # AS1280)) from WCM
UTUC tumors. Specimens were prepared for RNAseq using TruSeq RNA Library
Preparation Kit v2 or riboZero. RNA integrity was veriﬁed using the Agilent
Bioanalyzer 2100 (Agilent Technologies). cDNA was synthesized from total RNA
using Superscript III (Invitrogen). Sequencing was then performed on GAII, HiSeq
2000, or HiSeq 2500. All reads were independently aligned with STAR_2.4.0f138 for
sequence alignment against the human genome sequence build hg19, downloaded
via the UCSC genome browser (http://hgdownload.soe.ucsc.edu/goldenPath/hg19/
bigZips/), and SAMTOOLS v0.1.1939 for sorting and indexing reads. Cufﬂinks
(2.0.2)40 was used to estimate the expression values (FPKMS), and GENCODE
v2341 GTF ﬁle for annotation. Rstudio (1.0.136) with R (v3.3.2) and ggplot2 (2.2.1)
were used for the statistical analysis and the generation of ﬁgures. For fusion
analysis, we used STAR-fusion (STAR-Fusion_v0.5.1)42,43. Fusions with signiﬁcant
support of junction reads and spanning pairs are then selected and manually
reviewed. RNA was puriﬁed from BCM-MDA UTUC tumors and mRNA
expression was computed for all genes from RNAseq data31. Gene fusions were
detected in the RNAseq data using deFuse and SOAPfuse31.
RNAseq data quantiﬁcation, integration, and expression analysis. The mRNA
gene expression for high-grade WCM UTUC and TCGA UCB tumors was
quantiﬁed as Reads Per Kilobase of transcript per Million mapped reads (RPKMs).
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Similarly, RPKMs for high-grade tumors from a previously published UTUC
cohort at BCM and MDACC were calculated31. The RPKMs from these three
institutions were combined and quantile normalized to reduce any batch effects
among the samples while maintaining their individual biological variability. The
quantile normalized data were log transformed for further analyses. To rule out
batch effects, we examined the normalized expression values for a set of 40
housekeeping genes expected to have comparable expression value distributions
among the three datasets (WCM UTUC, BCM-MDA UTUC, TCGA UCB)
(Supplementary Fig. 1). Differential gene expression (DGE) between UTUC and
UCB cohorts was performed on the counts data using the Bioconductor package
DESeq2. The threshold to select differentially regulated genes was determined at a
fold change of >1 for upregulated and <−1 for downregulated genes and results
were deemed signiﬁcant at an adjusted p-value of 0.05 (Benjamini–Hochberg
correction).
Hierarchical clustering to infer UTUC subtypes. The subtypes in the UTUC
cohorts, namely WCM and BCM-MDA, were inferred using previously published
subtype-speciﬁc gene signatures together with previously reported2 subtype clas-
siﬁcations for TCGA UCB samples. To this end, ﬁrst, the normalized expression
values corresponding to the BASE47-signature, MDACC-signature, and TCGA-
signature genes were extracted from the three integrated data sets (namely WCM
UTUC, BCM-MDA UTUC, and TCGA UCB). For each signature gene set, the
subtype for each of the WCM UTUC and BCM-MDA UTUC samples was inferred
as follows: (1) The samples were clustered based on Pearson correlation and
average linkage, and the cophenetic distances among them were calculated, (2)
TCGA samples with minimum cophenetic distances to each UTUC sample were
identiﬁed, and corresponding TCGA subtype labels were assigned to the speciﬁc
UTUC samples. Subsequently, the results corresponding to each signature gene set
were visualized in heatmaps, scaled across signature genes, and grouped based on
inferred subtypes.
Unsupervised NMF. Unsupervised NMF was applied to the FPKM expression
matrix for TCGA and UTUC samples. The input expression matrix was ﬁrst
ﬁltered to retain only the top 25% of the genes with the highest expression
variability. The optimal number of ranks was estimated to three based on 30
randomly initialized instances using the NMF R package. The NMF was then run
with a rank k= 3 over 100 iterations, to obtain the ﬁnal deconvolution into three
resulting components. Amongst other genes, component 1 contained ECM/EMT
markers (C7, COMP, DES, PGM5, SFRP4, CLDN3, TWIST1), component 2
contained luminal/papillary markers (CIS.Down (CRTAC1, CTSE), luminal
(FGFR3, KRT20, SNX31, UPK1A, UPK2), and Sonic Hedgehog (SHH)), and
component 3 contained basal/squamous markers (basal (KRT5, KRT14, KRT6A),
immune (CXCL11, SAA1), and squamous (DSC3, GSDMC, PI3, TGM1). PCA was
then performed on the coefﬁcients obtained from NMF to visualize the separation
of the three components.
Outlier analysis. Genes expression outliers Z-scores were calculated for a list 74
cancer-related genes generated from the intersection of Sanger database and
Drugbank (https://www.drugbank.ca/
https://www.sanger.ac.uk/science/tools/gdsc-genomics-drug-sensitivity-cancer).
Z-scores were calculated across the WCM UTUC and BCM-MDA UTUC cohorts
for these 74 cancer-related genes. For each sample, the quantiles were calculated
and then used to compute the lower and upper bound to deﬁne an outlier. A cut-
off of Z-score > 1 and FPKMS > 50 was reported for the UTUC outlier genes after
comparison with TCGA UCB samples.
Identiﬁcation of T-cell-inﬂamed and T-cell-depleted subtypes. The top 5000
genes with the most variable normalized expression levels across TCGA UCB and
UTUC samples (WCM and BCM-MDA) were selected based on their median
absolute deviations. These genes data were then median centered and used as an
input for hierarchal clustering and Euclidean distance (linkage=ward.D2, k= 20).
A 170-gene cluster containing CD8A and other key immune genes was identiﬁed.
A k-means consensus clustering of these 170 genes across both UTUC and UCB
cohorts revealed the presence of two prominent subclusters that we labeled as T-
cell inﬂamed (with higher expression of cluster genes) and T-cell depleted (with
lower expression of cluster genes).
Differential expression analysis of FGFR3 shRNA dataset. To study the role of
FGFR3 in up-regulation of the interferon response, we obtained the publicly
available Affymetrix microarray dataset from the RT-112 bladder cancer cell
line, with or without shRNA-mediated knockdown of FGFR317,18. The dataset
comprised of 12 samples transduced with doxycycline-inducible shRNAs,
which were either a shRNA-targeting EGFP (control) or one of three distinct
shRNAs-targeting FGFR3 (FGFR3-shRNA); each condition had three biological
replicates. This data was downloaded as raw signal intensity values for 54,675
probesets (Affymetrix Human Genome U133 Plus 2.0 Array). We used robust
multiarray average (RMA) for background correction, normalization, and probe
level intensity calculation from Affy Bioconductor Package (Version 1.52), in R
statistical environment44. The normalized expression proﬁles were then used to
identify differentially expressed probes between FGFR3-shRNA versus control
samples using the limma package (version 3.30.13)45. Probes were collapsed to
gene level after taking the median fold change of the probes, utilizing hgu133-
plus2 annotation data46. Genes that were differentially expressed after doxycy-
cline induction in all three FGFR3-depleted cell lines but not in the control cell
line were considered putative FGFR3-regulated genes. We identiﬁed 58 up-
regulated genes (log-fold change > 1 and adjusted P-value < 0.05) and 45
downregulated genes. The log-fold change values of >1 or <−1 were used as
thresholds to select for up-regulated or down-regulated genes, respectively
(adjusted P-value < 0.05).
Gene set enrichment analysis. A pre-ranked gene set enrichment analysis
(GSEA) was applied to the differentially expressed genes, ordered based on their
log-fold change values, to identify the cellular pathways signiﬁcantly altered after
shRNA-mediated knockdown of FGFR347. Gene sets available through the Gene
Ontology Biological Pathways collection in the Molecular Signatures Database48
were used for the GSEA analysis.
Network analysis. Gene sets found to have a statistically signiﬁcant enrichment
using GSEA were visualized using network-based enrichment maps in Cytoscape49,
where each node in the network was representative of an individual gene set50. In
addition, the enrichment map also grouped redundant gene sets into distinct
clusters enabling the identiﬁcation of broader functional categories. The clusters
from the enrichment maps were further reﬁned and labeled using AutoAnnotate51.
We only focused on cancer-related and immune-related pathways in the network.
Real-time PCR. RT-4 and SW780 were purchased from ATCC (HTB-2 and
CRL-2169) and RT-112 was purchased from Sigma (85061106). RT-4, SW780
and RT-112 were cultured in McCoy’s 5A (modiﬁed) medium (Thermo Fisher
Scientiﬁc, 16600108), DMEM (Thermo Fisher Scientiﬁc, 11965118), and EMEM
(ATCC, 302003) with 10% FBS, respectively. All the cell lines were mycoplasma
negative and validated by STR testing. RT-112, RT4, and SW780 cells were
treated with DMSO, Erdaﬁtinib 1 μM, and Erdaﬁtinib 5 μM for 48 hours,
respectively. Total RNA was isolated with the RNeasy Plus Mini Kit (Qiagen
#74134) according to the manufacturer’s protocol. Total RNA concentration was
measured by NanoDrop (Thermo Fisher Scientiﬁc). cDNA was synthesized
using SuperScriptTM III First-Strand Synthesis system (Invitrogen #18080051).
Real-time PCR was performed by LightCycler 480 (Roche) using Power SYBR
Green Master Mix (Applied Biosystems #4367659). All calculations were col-
lected and analyzed with LightCycer 480 software (Roche) using the delta–delta
Ct method. The reaction components, conditions, and primers used are listed in
Supplementary Table 4. All data were normalized to the expression of the
housekeeping gene beta-actin (β-actin) and then compared to the expression in
the DMSO-treated group. Two independent experiments were performed, each
with two technical replicates. The data were presented by mean ± SD. P-values
were calculated using the t-test and corrected for multiple comparisons using the
Holm–Sidak method. All analyses were performed using GraphPad Prism sta-
tistical software.
Statistical analyses. For statistical tests, two-sided Mann–Whitney–Wilcoxon test
was used to check for signiﬁcant differences between two distributions. The two-
sided Fisher’s exact test was applied to determine whether the deviations between
the observed and the expected counts were signiﬁcant. When appropriate, P-values
were adjusted for multiple hypotheses testing with Benjamini–Hochberg proce-
dure. Boxplot statistics were computed with the function “boxplot” of R pro-
gramming language.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The genomic data that support the ﬁndings of this study are available in the database of
Genotypes and Phenotypes (dbGaP) and on cBioPortal for Cancer Genomics with the
identiﬁer https://www.cbioportal.org/study?id=utuc_cornell_baylor_mdacc_2019. The
source data underlying Figs. 1a–d, 2a–e, 3a, b, and 4a–f and Supplementary Figs. 1, 2, 3
and 4 are provided as a Source Data ﬁle.
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